Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform [1] Group 1: Product Development - The two developed molecules are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the US [1] - The combined formula product Groland has also received FDA registration, marking Jingtai's entry into the promising consumer health sector [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including tens of millions in upfront payments and milestone payments [1] - Eli Lilly will utilize Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also leveraging its AI antibody research platform to enhance internal pipeline research [1] - This partnership follows a previous $250 million collaboration between Jingtai Technology and Eli Lilly for AI small molecule drug development earlier in 2023 [1]

Core Viewpoint - Jingtai Holdings (02228) experienced a significant stock increase of over 6%, reaching HKD 11.4 with a trading volume of HKD 41.9461 million, following the announcement of a strategic collaboration with Eli Lilly valued at up to USD 345 million [1] Group 1: Strategic Collaboration - Jingtai Technology's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value potentially reaching USD 345 million, including several million dollars in upfront payments and milestone payments [1] - This collaboration aims to leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also utilizing its AI antibody research platform to enhance internal pipeline research [1] Group 2: Previous Collaborations - This agreement follows a previous collaboration in 2023, where Jingtai Technology and Eli Lilly signed a USD 250 million partnership focused on AI small molecule drugs, indicating a continued partnership between the two companies [1] Group 3: Ailux Development - Ailux, which has been a key focus for Jingtai Technology since 2021, has rapidly developed and commercialized its large molecule drug research platform over the past two years [1] - The platform employs a hybrid research model that combines AI-driven antibody drug design and engineering, effectively addressing the challenges of high costs and long timelines in drug discovery, enabling pharmaceutical companies to explore diverse targeting mechanisms and differentiated drug development pathways [1] - Ailux is expected to advance AI-designed next-generation antibody drugs into later clinical stages, aiming for more impactful major commercial collaborations in the future [1]

Core Insights - Jingtai Technology announced a strategic multi-target collaboration and platform licensing agreement with Eli Lilly, with a total value of up to $345 million [1] - The agreement includes several tens of millions of dollars in upfront payments and milestone payments [1] - Eli Lilly will leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas [1] - The AI antibody development platform will also be utilized to enhance Eli Lilly's internal pipeline research [1]